Metabolic risk factors and effect of alirocumab on cardiovascular events after acute coronary syndrome: a post-hoc analysis of the ODYSSEY OUTCOMES randomised controlled trial

Sustained Low-Density Lipoprotein Cholesterol Lowering With Alirocumab in ODYSSEY OUTCOMES

(2020) Shaun G. Goodman et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Peripheral Artery Disease and Venous Thromboembolic Events After Acute Coronary Syndrome

(2020) Gregory G. Schwartz et al.   CIRCULATION

Intensity of statin treatment after acute coronary syndrome, residual risk, and its modification by alirocumab: insights from the ODYSSEY OUTCOMES trial

(2020) Rafael Diaz et al.   European Journal of Preventive Cardiology

Efficacy and Safety of PCSK9 Inhibition With Evolocumab in Reducing Cardiovascular Events in Patients With Metabolic Syndrome Receiving Statin Therapy

(2020) Prakash Deedwania et al.   JAMA Cardiology

Effect of alirocumab on major adverse cardiovascular events according to renal function in patients with a recent acute coronary syndrome: prespecified analysis from the ODYSSEY OUTCOMES randomized clinical trial

(2020) José Tuñón et al.   EUROPEAN HEART JOURNAL

Discriminatory Capacity of Anthropometric Indices for Cardiovascular Disease in Adults: A Systematic Review and Meta-Analysis

(2020) Mitra Darbandi et al.   Preventing Chronic Disease

Patients with Recent Acute Coronary Syndrome and Polyvascular Disease Derive Large Absolute Benefit from Alirocumab: ODYSSEY OUTCOMES Trial

(2019) J. Wouter Jukema et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Effect of Alirocumab on Mortality After Acute Coronary Syndromes

(2019) Philippe Gabriel Steg et al.   CIRCULATION

2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk

(2019) François Mach et al.   EUROPEAN HEART JOURNAL

Effects of Alirocumab on Cardiovascular Events After Coronary Bypass Surgery

(2019) Shaun G. Goodman et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

(2019) Kausik K Ray et al.   Lancet Diabetes & Endocrinology

Effect of alirocumab on cardiovascular outcomes after acute coronary syndromes according to age: an ODYSSEY OUTCOMES trial analysis

(2019) Peter R Sinnaeve et al.   EUROPEAN HEART JOURNAL

Association of high-density lipoprotein particle concentration with cardiovascular risk following acute coronary syndrome: A case-cohort analysis of the dal-Outcomes trial

(2019) Taufiq Salahuddin et al.   AMERICAN HEART JOURNAL

Alirocumab Reduces Fatal and Nonfatal Cardiovascular Events

(2018) Michael Szarek et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome

(2018) Gregory G. Schwartz et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial

(2017) Marc S Sabatine et al.   Lancet Diabetes & Endocrinology

2016 European Guidelines on cardiovascular disease prevention in clinical practice

(2016) Massimo F. Piepoli et al.   EUROPEAN HEART JOURNAL

Cardiovascular and all-cause mortality in relation to various anthropometric measures of obesity in Europeans

(2015) X. Song et al.   NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES

Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: Rationale and design of the ODYSSEY Outcomes trial

(2014) Gregory G. Schwartz et al.   AMERICAN HEART JOURNAL

Comparison of various surrogate obesity indicators as predictors of cardiovascular mortality in four European populations

(2013) X Song et al.   EUROPEAN JOURNAL OF CLINICAL NUTRITION

Harmonizing the Metabolic Syndrome

(2009) K.G.M.M. Alberti et al.   CIRCULATION

Body mass index, waist circumference and waist:hip ratio as predictors of cardiovascular risk—a review of the literature

(2009) R Huxley et al.   EUROPEAN JOURNAL OF CLINICAL NUTRITION